Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry.
Expert review of neurotherapeutics January 1, 2022 Manaswini Pillai, Simon Erridge, Lara Bapir et al. 27 citations
Patients prescribed cannabis-based medicinal products for post-traumatic stress disorder showed significant improvements in PTSD symptoms, sleep, and anxiety at 1, 3, and 6 months, based on an analysis of 162 patients from the UK Medical Cannabis Registry. Most patients (88.89%) had previously or currently used cannabis. Median daily doses were 5.00 mg of cannabidiol and 145.00 mg of Δ9-tetrahydrocannabinol. Adverse events occurred in 20.37% of patients, with 135.8% of the total events reported; most were mild or moderate, and insomnia and fatigue were most common. The findings suggest acceptability and safety up to 6 months, but randomized placebo-controlled trials are needed to confirm causality and optimal dosing.